文献速递MDS 与骨髓增殖性肿瘤

CXCL8/CXCR2信号介导骨髓纤维化并是骨髓纤维化的治疗靶点

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.
PubMed 文献 · Blood · 2023-01-01

该研究在骨髓纤维化(MF)患者的原代细胞和人MPLW515L小鼠模型中,通过单细胞转录和细胞因子分泌研究,界定CXCL8/CXCR2信号在MF发病和骨髓纤维化进展中的作用。MF患者的造血干/祖细胞富集CXCL8/CXCR2基因特征,体外对外源性CXCL8配体反应表现为增殖和适应度增强。hMPLW515L过继转移模型中Cxcr2基因缺失可消除纤维化并延长总生存,药物抑制CXCR1/2通路改善血液学参数、减轻骨髓纤维化并与JAK抑制剂治疗协同。

要点

  • MF患者造血干/祖细胞富集CXCL8/CXCR2基因特征,体外对外源性CXCL8反应增殖增强。
  • hMPLW515L模型中Cxcr2基因缺失消除纤维化并延长总生存。
  • 药物抑制CXCR1/2通路改善血液学参数、减轻骨髓纤维化并与JAK抑制剂协同。

核心结论

  • CXCL8/CXCR2信号在MF发病和骨髓纤维化进展中起重要作用,为其治疗靶向提供机制依据。

研究设计与样本

  • 研究采用MF患者原代细胞的单细胞转录和细胞因子分泌研究,以及人MPLW515L小鼠MF模型。

主要发现

  • MF患者造血干/祖细胞富集CXCL8/CXCR2基因特征,体外对外源性CXCL8配体反应表现为增殖和适应度增强。
  • hMPLW515L过继转移模型中Cxcr2基因缺失消除纤维化并延长总生存。
  • 药物抑制CXCR1/2通路改善血液学参数、减轻骨髓纤维化并与JAK抑制剂治疗协同。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proinflammatory signaling is a hallmark feature of human cancer, including in myeloproliferative neoplasms (MPNs), most notably myelofibrosis (MF). Dysregulated inflammatory signaling contributes to fibrotic progression in MF; however, the individual cytokine mediators elicited by malignant MPN cells to promote collagen-producing fibrosis and disease evolution are yet to be fully elucidated. Previously, we identified a critical role for combined constitutive JAK/STAT and aberrant NF-κB proinflammatory signaling in MF development. Using single-cell transcriptional and cytokine-secretion studies of primary cells from patients with MF and the human MPLW515L (hMPLW515L) murine model of MF, we extend our previous work and delineate the role of CXCL8/CXCR2 signaling in MF pathogenesis and bone marrow fibrosis progression. Hematopoietic stem/progenitor cells from patients with MF are enriched for a CXCL8/CXCR2 gene signature and display enhanced proliferation and fitness in response to an exogenous CXCL8 ligand in vitro. Genetic deletion of Cxcr2 in the hMPLW515L-adoptive transfer model abrogates fibrosis and extends overall survival, and pharmacologic inhibition of the CXCR1/2 pathway improves hematologic parameters, attenuates bone marrow fibrosis, and synergizes with JAK inhibitor therapy. Our mechanistic insights provide a rationale for therapeutic targeting of the CXCL8/CXCR2 pathway among patients with MF.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Dunbar AJ, Kim D, Lu M, et al. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood. 2023. PMID: 36800567. doi:10.1182/blood.2022015418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。